Modern Drug Development Paradigms for Infectious Diseases

Abstract

The persistent threat of global pandemics, emerging zoonotic pathogens, and the rapid expansion of antimicrobial resistance (AMR) has highlighted the critical need for advanced therapeutic strategies in infectious disease management. Modern drug development has shifted from traditional, empirical screening toward interdisciplinary, targeted approaches that leverage artificial intelligence (AI), structural biology, and novel delivery systems. High-throughput screening (HTS) combined with model-informed drug development (MIDD) enables precise pharmacokinetics/pharmacodynamics (PK/PD) optimization and accelerates candidate identification while mitigating early-stage resistance risks. Concurrently, nanotheranostics and advanced nanocarriers are revolutionizing target specificity, enhancing bioavailability, and reducing off-target toxicity for difficult-to-treat infections such as multidrug-resistant tuberculosis and intracellular pathogens. Furthermore, to combat rapid pathogen mutation, researchers are increasingly prioritizing host-directed therapies (HDTs)—which modulate the host's immune response to eliminate pathogens—over pathogen-targeted agents alone. Despite these innovations, high clinical attrition rates, high development costs, and complex regulatory approval pathways for emerging threats remain significant hurdles. Continued progress relies on integrated cross-disciplinary collaboration, global surveillance, and adaptive clinical trial designs to ensure rapid and sustainable therapeutic responses to future infectious outbreaks.